Kestra Medical Technologies (NASDAQ:KMTS) CFO Sells $680,307.56 in Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 26,287 shares of the stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $25.88, for a total transaction of $680,307.56. Following the transaction, the chief financial officer directly owned 60,609 shares in the company, valued at $1,568,560.92. The trade was a 30.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Vaseem Mahboob also recently made the following trade(s):

• On Tuesday, August 4th, Vaseem Mahboob sold 6,995 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $24.68, for a total value of $172,636.60.
• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $23.80, for a total value of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.61, for a total value of $199,352.37.
• On Thursday, July 30th, Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.75, for a total value of $90,545.00.

Kestra Medical Technologies Stock Performance

Shares of KMTS traded down $0.45 during mid-day trading on Tuesday, hitting $27.90. The stock had a trading volume of 225,985 shares, compared to its average volume of 344,041. Kestra Medical Technologies, Ltd. has a fifty-two week low of $14.40 and a fifty-two week high of $30.00. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16. The company has a market cap of $1.63 billion, a PE ratio of -11.53 and a beta of 0.58. The company’s fifty day simple moving average is $23.13 and its two-hundred day simple moving average is $22.60.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The firm had revenue of $28.64 million for the quarter. On average, equities analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on KMTS. Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. JPMorgan Chase & Co. initiated coverage on shares of Kestra Medical Technologies in a research report on Monday. They set an “overweight” rating and a $30.00 price objective for the company. Wall Street Zen upgraded shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday. Wolfe Research set a $30.00 target price on shares of Kestra Medical Technologies in a report on Wednesday, July 15th. Finally, Oppenheimer started coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Kestra Medical Technologies presently has a consensus rating of “Hold” and a consensus price target of $28.14.

Institutional Investors Weigh In On Kestra Medical Technologies

Large investors have recently added to or reduced their stakes in the stock. Seven Grand Managers LLC bought a new stake in Kestra Medical Technologies in the fourth quarter valued at $2,652,000. Eventide Asset Management LLC grew its position in shares of Kestra Medical Technologies by 5.4% during the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after acquiring an additional 65,288 shares during the last quarter. Sei Investments Co. grew its position in shares of Kestra Medical Technologies by 22.6% during the first quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after acquiring an additional 43,753 shares during the last quarter. Summit Partners Public Asset Management LLC acquired a new stake in shares of Kestra Medical Technologies in the 4th quarter worth about $9,282,000. Finally, Jennison Associates LLC lifted its position in Kestra Medical Technologies by 15.0% in the 4th quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock valued at $5,817,000 after purchasing an additional 28,573 shares during the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.